CAJ | 학술논문

目的：探讨顺铂与洛铂在晚期卵巢癌腹腔化疗中的疗效及副反应。方法我科对2011-01～2012-12间收治的36例晚期卵巢癌术后患者进行回顾性分析，顺铂组16例，洛铂组20例，两组患者腹腔灌注时均予多西他赛全身化疗。结果两组患者CA125值术前与第1次灌注化疗前比较，无统计学差异（ P＞0.05）。第1次灌注化疗后，顺铂组与洛铂组比较无统计学意义（ P＞0.05），而第2次、第3次及第4次化疗后两组的CA125值比较，仍无统计差异（ P＞0.05）；顺铂组与洛铂组术后有肉眼残留病灶的患者经第1次与第2次化疗后，顺铂组的CA125降到更低水平（ P＜0.05）；两组在副反应方面（血红蛋白下降、白细胞下降、肝功能损伤及消化道反应方面）顺铂组与洛铂组无统计学差异，肾功能损伤发生率顺铂组高于洛铂组，血小板下降发生率顺铂组低于洛铂组。结论晚期卵巢癌患者经过肿瘤细胞减灭术后合并腹水，予顺铂或洛铂行腹腔灌注化疗，并结合多西他赛全身化疗，均有效可行，而对有肉眼残留病灶的患者，予顺铂腹腔灌注化疗可能在比较短的疗程内见效。
목적：탐토순박여락박재만기란소암복강화료중적료효급부반응。방법아과대2011-01～2012-12간수치적36례만기란소암술후환자진행회고성분석，순박조16례，락박조20례，량조환자복강관주시균여다서타새전신화료。결과량조환자CA125치술전여제1차관주화료전비교，무통계학차이（ P＞0.05）。제1차관주화료후，순박조여락박조비교무통계학의의（ P＞0.05），이제2차、제3차급제4차화료후량조적CA125치비교，잉무통계차이（ P＞0.05）；순박조여락박조술후유육안잔류병조적환자경제1차여제2차화료후，순박조적CA125강도경저수평（ P＜0.05）；량조재부반응방면（혈홍단백하강、백세포하강、간공능손상급소화도반응방면）순박조여락박조무통계학차이，신공능손상발생솔순박조고우락박조，혈소판하강발생솔순박조저우락박조。결론만기란소암환자경과종류세포감멸술후합병복수，여순박혹락박행복강관주화료，병결합다서타새전신화료，균유효가행，이대유육안잔류병조적환자，여순박복강관주화료가능재비교단적료정내견효。
Objective To evaluate efficacy and toxicity of cisplatin and lobaplatin in intraperitoneal perfusion chemotherapy for ad -vanced ovarian cancer with ascites .Methods Retrospective analysis was used to analyze the clinical materials of 36 cases about postopera-tive advanced ovarian cancer in Oncology Department of the People′s Hospital, Province Guizhou from January 2011 to December 2012, with 16 cases in cisplatin group(A group) and 20 cases in lobaplatin group(B group).Docetaxel chemotherapy was used on all the patients during intraperitoneal perfusion .Results There was no significant difference in CA 125 between A group and B group in first pre and post chemotherapy (P>0.05).There was no statistical significance between two groups after the second ,third and fourth cycle chemotherapy (P>0.05).But for the patients with gross residual disease ,after the first or second cycle chemotherapy , CA125 levels in A group were lower than that in B group (P<0.05).There were no statistical significance between two groups in the toxicities of hemoglobin , lower white blood cell, digestive disturbance and liver function damage;but A group were higher than that in B group in platelet decrease and renal function damage.Conclusion Intraperitoneal perfusion chemotherapy with cisplatin or lobaplatin is efficient and suitable for the advanced ovarian cancer with ascites after optimally cytoreductive surgery ,but cisplatin lowered recent CA 125 level will get sooner result than lobaplatin for those with gross residual disease .